Northern Trust’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,658,188
| Closed | -$6.8M | – | 4842 |
|
|
2022
Q1 | $6.8M | Sell |
1,658,188
-58,245
| -3% | -$211K | ﹤0.01% | 2389 |
|
|
2021
Q4 | $6.13M | Sell |
1,716,433
-21,317
| -1% | -$74.6K | ﹤0.01% | 2566 |
|
|
2021
Q3 | $6.33M | Sell |
1,737,750
-20,975
| -1% | -$84.8K | ﹤0.01% | 2588 |
|
|
2021
Q2 | $7.67M | Sell |
1,758,725
-8,566
| -0.5% | -$34.9K | ﹤0.01% | 2556 |
|
|
2021
Q1 | $7.26M | Sell |
1,767,291
-114,910
| -6% | -$498K | ﹤0.01% | 2506 |
|
|
2020
Q4 | $7.51M | Sell |
1,882,201
-46,216
| -2% | -$150K | ﹤0.01% | 2435 |
|
|
2020
Q3 | $5.21M | Sell |
1,928,417
-113,366
| -6% | -$314K | ﹤0.01% | 2506 |
|
|
2020
Q2 | $5.62M | Buy |
2,041,783
+100,263
| +5% | +$280K | ﹤0.01% | 2445 |
|
|
2020
Q1 | $4.58M | Sell |
1,941,520
-4,097
| -0.2% | -$13.9K | ﹤0.01% | 2354 |
|
|
2019
Q4 | $9.14M | Sell |
1,945,617
-288,342
| -13% | -$1.18M | ﹤0.01% | 2231 |
|
|
2019
Q3 | $7.47M | Buy |
2,233,959
+434,901
| +24% | +$1.43M | ﹤0.01% | 2322 |
|
|
2019
Q2 | $5.92M | Buy |
1,799,058
+29,578
| +2% | +$85.6K | ﹤0.01% | 2472 |
|
|
2019
Q1 | $5.36M | Buy |
1,769,480
+27,878
| +2% | +$90.3K | ﹤0.01% | 2524 |
|
|
2018
Q4 | $4.74M | Buy |
1,741,602
+6,868
| +0.4% | +$22.6K | ﹤0.01% | 2537 |
|
|
2018
Q3 | $5.83M | Buy |
1,734,734
+16,483
| +1% | +$50.9K | ﹤0.01% | 2603 |
|
|
2018
Q2 | $4.43M | Buy |
1,718,251
+119,091
| +7% | +$296K | ﹤0.01% | 2740 |
|
|
2018
Q1 | $3.52M | Sell |
1,599,160
-16,851
| -1% | -$37.9K | ﹤0.01% | 2791 |
|
|
2017
Q4 | $3.22M | Sell |
1,616,011
-12,284
| -0.8% | -$26.7K | ﹤0.01% | 2863 |
|
|
2017
Q3 | $5.28M | Sell |
1,628,295
-25,971
| -2% | -$80.1K | ﹤0.01% | 2598 |
|
|
2017
Q2 | $5.33M | Buy |
1,654,266
+1,368,131
| +478% | +$3.88M | ﹤0.01% | 2590 |
|
|
2017
Q1 | $813K | Buy |
286,135
+21,163
| +8% | +$50.9K | ﹤0.01% | 3416 |
|
|
2016
Q4 | $617K | Sell |
264,972
-13,242
| -5% | -$25.2K | ﹤0.01% | 3477 |
|
|
2016
Q3 | $467K | Buy |
278,214
+26,026
| +10% | +$31.9K | ﹤0.01% | 3527 |
|
|
2016
Q2 | $265K | Sell |
252,188
-1,397,143
| -85% | -$1.35M | ﹤0.01% | 3650 |
|
|
2016
Q1 | $1.44M | Buy |
1,649,331
+5,507
| +0.3% | +$5.33K | ﹤0.01% | 3133 |
|
|
2015
Q4 | $1.99M | Buy |
1,643,824
+19,673
| +1% | +$27.4K | ﹤0.01% | 3070 |
|
|
2015
Q3 | $2.76M | Buy |
1,624,151
+152,465
| +10% | +$299K | ﹤0.01% | 2842 |
|
|
2015
Q2 | $3.06M | Buy |
1,471,686
+201,550
| +16% | +$489K | ﹤0.01% | 2830 |
|
|
2015
Q1 | $3.44M | Buy |
1,270,136
+1,486
| +0.1% | +$3.77K | ﹤0.01% | 2751 |
|
|
2014
Q4 | $3.26M | Sell |
1,268,650
-53,622
| -4% | -$120K | ﹤0.01% | 2776 |
|
|
2014
Q3 | $2.42M | Buy |
1,322,272
+8,875
| +0.7% | +$19.3K | ﹤0.01% | 2979 |
|
|
2014
Q2 | $3.51M | Sell |
1,313,397
-154,603
| -11% | -$465K | ﹤0.01% | 2759 |
|
|
2014
Q1 | $5.14M | Sell |
1,468,000
-133,589
| -8% | -$593K | ﹤0.01% | 2530 |
|
|
2013
Q4 | $7.16M | Buy |
1,601,589
+23,424
| +1% | +$95.4K | ﹤0.01% | 2312 |
|
|
2013
Q3 | $6.41M | Buy |
1,578,165
+63,063
| +4% | +$275K | ﹤0.01% | 2335 |
|
|
2013
Q2 | $6.3M | Buy |
+1,515,102
| New | +$5.85M | ﹤0.01% | 2261 |
|
Other funds holding ATRS
Northern Trust's ATRS Position: Q2 2022 in Review
Northern Trust sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 1,658,188 shares — an estimated $6.8M sold.
Northern Trust first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $9.14M in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Northern Trust reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Northern Trust sold 1,658,188 Antares Pharma, Inc. shares in Q2 2022, an estimated $6.8M.
- Northern Trust first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- Northern Trust's Antares Pharma, Inc. position peaked at $9.14M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Northern Trust's 13F filing for Q2 2022, filed 12 Aug 2022.